CN104415060A - Edible composition as well as preparation method and application thereof - Google Patents
Edible composition as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN104415060A CN104415060A CN201310391108.3A CN201310391108A CN104415060A CN 104415060 A CN104415060 A CN 104415060A CN 201310391108 A CN201310391108 A CN 201310391108A CN 104415060 A CN104415060 A CN 104415060A
- Authority
- CN
- China
- Prior art keywords
- eubacterium
- inulin
- group
- takes
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title abstract description 24
- 229920001202 Inulin Polymers 0.000 claims abstract description 136
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 136
- 229940029339 inulin Drugs 0.000 claims abstract description 136
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims abstract description 95
- 241000894006 Bacteria Species 0.000 claims abstract description 62
- 241001465754 Metazoa Species 0.000 claims abstract description 48
- 230000000968 intestinal effect Effects 0.000 claims abstract description 39
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 26
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 23
- 206010020772 Hypertension Diseases 0.000 claims abstract description 21
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 20
- 208000008589 Obesity Diseases 0.000 claims abstract description 20
- 235000020824 obesity Nutrition 0.000 claims abstract description 20
- 230000002708 enhancing effect Effects 0.000 claims abstract description 19
- 230000036039 immunity Effects 0.000 claims abstract description 19
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 18
- 230000001105 regulatory effect Effects 0.000 claims abstract description 11
- 239000002775 capsule Substances 0.000 claims description 153
- 230000000813 microbial effect Effects 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 29
- 241000193171 Clostridium butyricum Species 0.000 claims description 25
- 241000186528 Clostridium tertium Species 0.000 claims description 24
- 241001531188 [Eubacterium] rectale Species 0.000 claims description 24
- 241000186401 Eubacterium oxidoreducens Species 0.000 claims description 23
- 241001531190 Eubacterium ramulus Species 0.000 claims description 23
- 241001531192 Eubacterium ventriosum Species 0.000 claims description 23
- 241000186399 Holdemanella biformis Species 0.000 claims description 23
- 241000604449 Megasphaera Species 0.000 claims description 23
- 238000002156 mixing Methods 0.000 claims description 21
- 230000002265 prevention Effects 0.000 claims description 18
- 235000013376 functional food Nutrition 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 11
- 241000605909 Fusobacterium Species 0.000 claims description 8
- 230000003203 everyday effect Effects 0.000 claims description 7
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 6
- 241000186394 Eubacterium Species 0.000 claims description 6
- 241000589516 Pseudomonas Species 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 241000607142 Salmonella Species 0.000 claims description 4
- 241001531197 [Eubacterium] hallii Species 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 229920001688 coating polymer Polymers 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 239000007888 film coating Substances 0.000 claims description 2
- 238000009501 film coating Methods 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000004014 plasticizer Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 24
- 241000186660 Lactobacillus Species 0.000 abstract description 19
- 229940039696 lactobacillus Drugs 0.000 abstract description 19
- 239000006041 probiotic Substances 0.000 abstract description 19
- 235000018291 probiotics Nutrition 0.000 abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 9
- 241000186000 Bifidobacterium Species 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 239000000843 powder Substances 0.000 description 57
- 239000007901 soft capsule Substances 0.000 description 57
- 210000004369 blood Anatomy 0.000 description 27
- 239000008280 blood Substances 0.000 description 27
- 239000000463 material Substances 0.000 description 26
- 241000186016 Bifidobacterium bifidum Species 0.000 description 22
- 238000005516 engineering process Methods 0.000 description 22
- 238000004519 manufacturing process Methods 0.000 description 22
- 238000011160 research Methods 0.000 description 21
- 238000012545 processing Methods 0.000 description 20
- 239000008188 pellet Substances 0.000 description 19
- 230000000529 probiotic effect Effects 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 16
- 230000037396 body weight Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 11
- 230000009286 beneficial effect Effects 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 238000012258 culturing Methods 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 210000000577 adipose tissue Anatomy 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 235000012054 meals Nutrition 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 230000035487 diastolic blood pressure Effects 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 201000005577 familial hyperlipidemia Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000005180 public health Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000003345 hyperglycaemic effect Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 241000588807 Bordetella Species 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 101710146739 Enterotoxin Proteins 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 241000282894 Sus scrofa domesticus Species 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000147 enterotoxin Substances 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 108010062877 Bacteriocins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000002011 intestinal secretion Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses an edible composition as well as a preparation method and application thereof. The edible composition comprises inulin and butyric acid producing bacteria in a weight ratio of 1 to 1. Inulin and butyric acid producing bacteria in the edible composition have synergistic effects and can conduce to obviously increasing the concentrations of butyric acids in intestinal tracts of animals and the quantities of probiotics, such as lactobacillus and bifidobacterium, and inhibiting growth of harmful bacteria, thus effectively regulating intestinal floras of animals and then enhancing the immunities based on the effects of the intestinal floras and preventing or treating the diseases, such as obesity, diabetes mellitus, hypertension, hyperlipidemia or tumors.
Description
Technical field
The present invention relates to edible composition and its production and use, particularly, relate to edible composition and preparation method thereof and the purposes in adjustment microbial population of animal intestinal tract and prevention or treatment diabetes, hyperlipidemia, hypertension, obesity or tumor.More specifically, the present invention relates to edible composition, prepare the method for edible composition, edible composition is preparing the purposes in medicine, medicine and functional food.
Background technology
About 10 are perched in human gastrointestinal tract
4the normal flora of the order of magnitude, its total amount and liver similar.Enteric microorganism contains miscellaneous enzyme system, can participate in a series of physiological process such as host's energy, material and hereditary information transhipment.Existing many research proves, enteric microorganism can form biological barrier at intestinal, by occupation time process, nutrient competition and the undue growth of rejection condition pathogenic bacterium and the invasion of external pathogenic bacterium such as secreted various metabolite and bacteriocin.Increasing evidence shows, the intestinal microbial population of structural imbalance has a very important role in the generation, development of obesity, diabetes chronic diseases.
But, regulate the research of microbial population of animal intestinal tract aspect still to need deeply.
Summary of the invention
The present invention is intended at least to solve one of technical problem existed in prior art.For this reason, one object of the present invention is to propose one for regulating microbial population of animal intestinal tract, enhancing immunity, the edible composition of prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor.
Inventor studies discovery: inulin can promote the growth of producing butanoic acid bacterial strain, thus the concentration of butanoic acid in increase intestinal, in addition, the selective proliferative substrate of inulin or the probiotic bacteria such as bacillus bifidus and lactobacillus, the growth of the probiotic bacteria such as lactobacillus and bacillus bifidus can be promoted, and the growth of the probiotic bacteria such as lactobacillus and bacillus bifidus can suppress harmful bacteria to increase, prevention and the disorder of alleviation function of intestinal canal, reduce serum cholesterol, antitumor, enhancing immunity, slow down aging, promote calcium, the absorption etc. of the metal ions such as magnesium, thus positive influences are produced to health.The acetic acid of the probiotic bacteria such as bacillus bifidus and lactobacillus generation simultaneously and lactic acid, can be utilized by probiotic bacterias such as product butyrics again and generate butanoic acid, and produce butyric acid bacteria in butyric can with the intestinal beneficial bacterium symbiosis such as bacillus bifidus, bacillus acidophilus and streptococcus faecalis, its fermented product extract can promote the growth of these intestinal beneficial bacteriums significantly simultaneously.The discovery that inventor is surprised, inulin is combined with product butyric, make full use of the chemiluminescence between inulin, probiotic bacteria such as primary bowel such as product butyric, bacillus bifidus etc., can at a large amount of butanoic acid of intestinal secretion, the growth of the primary bowel probiotic bacterias such as bacillus bifidus can be promoted again, treatment relevant disease Be very effective.
Thus, according to an aspect of the present invention, the invention provides a kind of edible composition.According to embodiments of the invention, this edible composition comprises: weight ratio is the inulin of 1:1 and produces butyric.According to embodiments of the invention, inulin can promote to produce the growth of butanoic acid bacterial strain and the growth of the probiotic bacteria such as lactobacillus and bacillus bifidus, the acetic acid of the probiotic bacteria such as bacillus bifidus and lactobacillus generation simultaneously and lactic acid, can be utilized by probiotic bacterias such as product butyrics again and generate butanoic acid, and the butyric acid bacteria energy produced in butyric and bacillus bifidus, the symbiosis of the intestinal beneficial bacterium such as bacillus acidophilus and streptococcus faecalis, its fermented product extract can promote the growth of these intestinal beneficial bacteriums significantly simultaneously, thus quantity and the butyric acid density of the probiotic bacteria such as bacillus bifidus and lactobacillus in animal intestinal can be significantly improved, remarkable adjustment microbial population of animal intestinal tract, and then performance enhancing immunity, prevention or treatment obesity, diabetes, hypertension, the effect such as hyperlipidemia or tumor.Thus, give edible composition of the present invention to animal, can effectively regulate its intestinal microbial population, and then can enhancing immunity, the diseases such as prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor.
It should be noted that, the animal species of term " animal " indication in expression way " adjustment microbial population of animal intestinal tract " used in this article is not particularly limited.According to embodiments of the invention, this animal can be any animal with intestinal organ, and preferred mammal, more preferably rat, mice, people, optimum is chosen.In addition, used in this article expression way " prevention or treatment " mainly refers to the diseases such as prevention or auxiliary treatment obesity, diabetes, hypertension, hyperlipidemia and tumor.
According to embodiments of the invention, the grain diameter of described inulin and described product butyric is not particularly limited.According to some embodiments of the present invention, the grain diameter of described inulin and described product butyric is all not more than 100 microns.Thus, make inulin, produce butyric raw material and reach micronization, be more conducive to absorption of human body.
According to embodiments of the invention, the kind of described product butyric is not particularly limited.According to some embodiments of the present invention, described product butyric produces butanoic acid Pseudomonas for being selected from, at least one of fusobacterium, Eubacterium and Fusobacterium.According to concrete examples more of the present invention, described product butyric be selected from clostridium butyricum, at least one that butyric acid bacteria, clostridium tertium, Eubacterium ventriosum, Eubacterium biforme, Eubacterium rectale, Eubacterium ramulus, Eubacterium oxidoreducens, Ai Shi Megasphaera, polyacid light hilllock Salmonella, Eubacterium hallii, Pu Shi dwell bacillus faecalis.Thus, can effectively improve butyric acid density in animal intestinal, promote propagation and the growth of the beneficial flora such as bacillus bifidus and lactobacillus, suppress the growth of harmful bacteria and putrefaction bacteria, breeding, correct enteric flora disturbance, reduce the generation of enterotoxin, thus effectively regulate microbial population of animal intestinal tract, and then performance enhancing immunity, the effects such as prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor.
According to embodiments of the invention, the viable count producing butyric described in edible composition is not particularly limited, as long as effectively can regulate microbial population of animal intestinal tract.According to some embodiments of the present invention, the viable count of described product butyric is not less than 1.0*10
8cFU/g.Thus, can effectively improve butyric acid density in animal intestinal, promote that the probiotic bacteria such as bacillus bifidus and lactobacillus increases, thus effectively regulate microbial population of animal intestinal tract, and then can enhancing immunity, the diseases such as prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor.
According to embodiments of the invention, edible edible composition of the present invention is without any side effect, thus the edible dosage of described edible composition is not particularly limited, as long as can improve the quantity of the beneficial flora such as bacillus bifidus and lactobacillus in animal intestinal and effectively regulate microbial population of animal intestinal tract.According to some embodiments of the present invention, the edible dosage of described edible composition is 200-400mg/kg every day, preferred 300mg/kg.Thus, in the intestinal being given the animal of edible composition, the quantity of the beneficial flora such as bacillus bifidus and lactobacillus obviously increases, butyric acid density improves, and harmful bacteria and putrefaction bacteria quantity reduce, and namely edible composition of the present invention regulates the Be very effective of microbial population of animal intestinal tract.
According to a further aspect in the invention, present invention also offers a kind of method preparing foregoing edible composition.According to embodiments of the invention, the method comprises: the inulin and the product butyric Homogeneous phase mixing that by weight ratio are 1:1.Thus, utilize method of the present invention to prepare foregoing edible composition, processing ease, equipment is simple, with low cost, be easy to realize large-scale production.
According to embodiments of the invention, the grain diameter of described inulin and described product butyric is not particularly limited.According to some embodiments of the present invention, the grain diameter of described inulin and described product butyric is all not more than 100 microns.Thus, make inulin, produce butyric raw material and reach micronization, be more conducive to absorption of human body.
According to embodiments of the invention, the kind of described product butyric is not particularly limited.According to some embodiments of the present invention, described product butyric produces butanoic acid Pseudomonas for being selected from, at least one of fusobacterium, Eubacterium and Fusobacterium.According to concrete examples more of the present invention, described product butyric be selected from clostridium butyricum, at least one that butyric acid bacteria, clostridium tertium, Eubacterium ventriosum, Eubacterium biforme, Eubacterium rectale, Eubacterium ramulus, Eubacterium oxidoreducens, Ai Shi Megasphaera, polyacid light hilllock Salmonella, Eubacterium hallii, Pu Shi dwell bacillus faecalis.Thus, can effectively improve butyric acid density in animal intestinal, promote propagation and the growth of the beneficial flora such as bacillus bifidus and lactobacillus, suppress the growth of harmful bacteria and putrefaction bacteria, breeding, correct enteric flora disturbance, reduce the generation of enterotoxin, thus effectively regulate microbial population of animal intestinal tract, and then performance enhancing immunity, the effects such as prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor.
According to embodiments of the invention, the viable count producing butyric described in edible composition is not particularly limited, as long as effectively can regulate microbial population of animal intestinal tract.According to some embodiments of the present invention, the viable count of described product butyric is not less than 1.0*10
8cFU/g.Thus, can effectively improve butyric acid density in animal intestinal, promote that the probiotic bacteria such as bacillus bifidus and lactobacillus increases, thus effectively regulate microbial population of animal intestinal tract, and then can enhancing immunity, the diseases such as prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor.
According to another aspect of the invention, regulating the effect in microbial population of animal intestinal tract based on above-mentioned edible composition, present invention also offers edible composition and preparing the purposes in medicine, described medicine is for regulating microbial population of animal intestinal tract.
Said medicine can be used in regulating microbial population of animal intestinal tract, and then can play the effects such as enhancing immunity, fat-reducing, blood sugar lowering, blood pressure lowering, blood fat reducing, antitumor by the effect of intestinal microbial population.Thus, according to embodiments of the invention, described medicine is used for enhancing immunity, prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor.
In accordance with a further aspect of the present invention, present invention also offers a kind of medicine.According to embodiments of the invention, this pharmaceutical pack contains: foregoing edible composition; And pharmaceutically acceptable excipient.Inventor is surprised to find, medicine of the present invention can significantly improve quantity and the butyric acid density of the probiotic bacteria such as bacillus bifidus and lactobacillus in animal intestinal, thus effectively regulate microbial population of animal intestinal tract, and then pass through the effective enhancing immunity of effect of intestinal microbial population, the diseases such as prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor.
According to embodiments of the invention, the kind of excipient is not particularly limited, as long as medicine can be made to form the dosage form of easily carrying out administration.According to concrete examples more of the present invention, described excipient is at least one being selected from binding agent, filler, film-coating polymer, plasticizer, fluidizer, disintegrating agent and lubricant.
According to embodiments of the invention, the dosage form of medicine of the present invention is not particularly limited, as long as can be convenient to carry out administration.According to concrete examples more of the present invention, described medicine is in the form of at least one being selected from capsule, pill, tablet, granule, liquid oral, oral pastes, aerosol and spray.According to preferred embodiments more of the present invention, described medicine is the form of capsule.Thus, be easy to carry out administration.
According to embodiments of the invention, the dosage of medicine of the present invention is not particularly limited, and in practical application, can select flexibly according to the health status of administration object.According to some embodiments of the present invention, the dosage of described medicine is 100-200mg inulin/kg every day, preferred 150mg inulin/kg.Thus, significantly improved by the quantity of the probiotic bacteria such as bacillus bifidus and lactobacillus in administration animal intestinal, butyric acid density obviously increases, and harmful bacteria and putrefaction bacteria quantity obviously reduce, and namely regulate the Be very effective of microbial population of animal intestinal tract.
According to embodiments of the invention, described medicine is for regulating microbial population of animal intestinal tract.And then, the effects such as enhancing immunity, fat-reducing, blood sugar lowering, blood pressure lowering, blood fat reducing, antitumor can be played by the effect of intestinal microbial population.Thus, according to other embodiments of the present invention, described medicine is used for enhancing immunity, prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor.
According to another aspect of the invention, present invention also offers a kind of functional food.According to embodiments of the invention, this functional food comprises: foregoing edible composition; And acceptable additive in bromatology.According to embodiments of the invention, functional food of the present invention can significantly improve by the quantity of the probiotic bacteria such as bacillus bifidus, lactobacillus in administration animal intestinal and butyric acid density, the intestinal microbial population of effective adjustment animal, and then effectively prevent or treat the diseases such as obesity, diabetes, hypertension, hyperlipidemia or tumor by the effect of intestinal microbial population.
It should be noted that, term " functional food " used in this article should make broad understanding, its can be any can by the form eaten, namely except the food form of routine, food of the present invention can also be health product, beverage etc.In addition, term " administration " used in this article should make broad understanding, except the drug administration of routine, to feed for can be understood as during food or to provide this food animal.
According to embodiments of the invention, the edible dosage of functional food of the present invention is not particularly limited, as long as can improve the quantity of the beneficial flora such as bacillus bifidus and lactobacillus in animal intestinal and effectively regulate microbial population of animal intestinal tract.According to some embodiments of the present invention, the edible dosage of described functional food is 100-200mg inulin/kg every day, preferred 150mg inulin/kg.Thus, in the intestinal of the animal of edible described functional food, the quantity of the beneficial flora such as bacillus bifidus and lactobacillus obviously increases, and harmful bacteria and putrefaction bacteria quantity reduce, and namely described functional food regulates the Be very effective of microbial population of animal intestinal tract.
According to embodiments of the invention, described functional food is for regulating microbial population of animal intestinal tract.And then, the effects such as enhancing immunity, fat-reducing, blood sugar lowering, blood pressure lowering, blood fat reducing, antitumor can be played by the effect of intestinal microbial population.Thus, according to other embodiments of the present invention, described functional food is used for enhancing immunity, prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor.
Additional aspect of the present invention and advantage will part provide in the following description, and part will become obvious from the following description, or be recognized by practice of the present invention.
Detailed description of the invention
Embodiments of the invention are described below in detail.Embodiment described below is exemplary, only for explaining the present invention, and can not be interpreted as limitation of the present invention.Unreceipted concrete technology or condition in embodiment, according to the technology described by the document in this area or condition or carry out according to product description.Agents useful for same or the unreceipted production firm person of instrument, being can by the conventional products of commercial acquisition.
Embodiment 1
1, the preparation of inulin capsule
Take inulin 10 weight portion, adopt research of super-pine crush equipment processing to pulverize, obtain the inulin fine powder that grain diameter is 100 microns, its homogenizing is become mixing fine powders, then content material is placed in soft capsule pellet press, fills according to existing soft capsule production technology and be pressed into soft capsule.
2, the preparation of clostridium butyricum viable capsule
Take clostridium butyricum (ATCC article number 19398) 10 weight portions, research of super-pine crush equipment processing is adopted to pulverize, obtain the clostridium butyricum fine powder that clostridium butyricum grain diameter is 100 microns, its homogenizing is become mixing fine powders, then content material is placed in soft capsule pellet press, fills according to existing soft capsule production technology and be pressed into soft capsule.
3, containing the preparation of the clostridium butyricum viable capsule of inulin
First, with liquid or solid culture medium culturing clostridium butyricum (ATCC article number 19398) strain, then collect and wash thalline, drying is prepared into active microbe powder, then inulin 5 weight portion, clostridium butyricum active microbe powder 5 weight portion is taken, research of super-pine crush equipment processing is adopted to pulverize, obtain inulin, clostridium butyricum fine powder that grain diameter is 100 microns, its homogenizing is become mixing fine powders, then content material is placed in soft capsule pellet press, fills according to existing soft capsule production technology and be pressed into soft capsule.
4, the preparation of butyric acid bacteria viable capsule
Take butyric acid bacteria (ATCC article number 859) 10 weight portions, research of super-pine crush equipment processing is adopted to pulverize, obtain the butyric acid bacteria fine powder that grain diameter is 100 microns, its homogenizing is become mixing fine powders, then content material is placed in soft capsule pellet press, fills according to existing soft capsule production technology and be pressed into soft capsule.
5, containing the preparation of the butyric acid bacteria viable capsule of inulin
First, with liquid or solid culture medium culturing butyric acid bacteria (ATCC article number 859) strain, then collect and wash thalline, drying is prepared into active microbe powder, then takes inulin 5 weight portion, butyric acid bacteria active microbe powder 5 weight portion, adopts research of super-pine crush equipment processing to pulverize, obtain inulin, butyric acid bacteria fine powder that grain diameter is 100 microns, its homogenizing is become mixing fine powders, then content material is placed in soft capsule pellet press, fill according to existing soft capsule production technology and be pressed into soft capsule.
6, the preparation of clostridium tertium viable capsule
Take clostridium tertium (ATCC article number 19405) 10 weight portions, research of super-pine crush equipment processing is adopted to pulverize, obtain the clostridium tertium fine powder that grain diameter is 100 microns, its homogenizing is become mixing fine powders, then content material is placed in soft capsule pellet press, fills according to existing soft capsule production technology and be pressed into soft capsule.
7, containing the preparation of the clostridium tertium viable capsule of inulin
First liquid or solid culture medium culturing clostridium tertium (ATCC article number 19405) strain is used, then collect and wash thalline, drying is prepared into active microbe powder, then inulin 5 weight portion, clostridium tertium active microbe powder 5 weight portion is taken, research of super-pine crush equipment processing is adopted to pulverize, obtain inulin, clostridium tertium fine powder that grain diameter is 100 microns, its homogenizing is become mixing fine powders, then content material is placed in soft capsule pellet press, fills according to existing soft capsule production technology and be pressed into soft capsule.
8, the preparation of Eubacterium ventriosum viable capsule
Take Eubacterium ventriosum (ATCC article number 27560) 10 weight portions, research of super-pine crush equipment processing is adopted to pulverize, obtain the Eubacterium ventriosum fine powder that grain diameter is 100 microns, its homogenizing is become mixing fine powders, then content material is placed in soft capsule pellet press, fills according to existing soft capsule production technology and be pressed into soft capsule.
9, containing the preparation of the Eubacterium ventriosum viable capsule of inulin
First, with liquid or solid culture medium culturing Eubacterium ventriosum (ATCC article number 27560) strain, then collect and wash thalline, drying is prepared into active microbe powder, then inulin 5 weight portion, Eubacterium ventriosum active microbe powder 5 weight portion is taken, research of super-pine crush equipment processing is adopted to pulverize, obtain inulin, Eubacterium ventriosum fine powder that grain diameter is 100 microns, its homogenizing is become mixing fine powders, then content material is placed in soft capsule pellet press, fills according to existing soft capsule production technology and be pressed into soft capsule.
10, the preparation of Eubacterium biforme viable capsule
Take Eubacterium biforme (ATCC article number 27806) 10 weight portions, research of super-pine crush equipment processing is adopted to pulverize, obtain the Eubacterium biforme fine powder that grain diameter is 100 microns, its homogenizing is become mixing fine powders, then content material is placed in soft capsule pellet press, fills according to existing soft capsule production technology and be pressed into soft capsule.
11, containing the preparation of the Eubacterium biforme viable capsule of inulin
First, with liquid or solid culture medium culturing Eubacterium biforme (ATCC article number 27806) strain, then collect and wash thalline, drying is prepared into active microbe powder, then inulin 5 weight portion, Eubacterium biforme active microbe powder 5 weight portion is taken, research of super-pine crush equipment processing is adopted to pulverize, obtain inulin, Eubacterium biforme fine powder that grain diameter is 100 microns, its homogenizing is become mixing fine powders, then content material is placed in soft capsule pellet press, fills according to existing soft capsule production technology and be pressed into soft capsule.
12, the preparation of Eubacterium rectale viable capsule
Take Eubacterium rectale (ATCC article number 33656) 10 weight portions, research of super-pine crush equipment processing is adopted to pulverize, obtain the Eubacterium rectale fine powder that grain diameter is 100 microns, its homogenizing is become mixing fine powders, then content material is placed in soft capsule pellet press, fills according to existing soft capsule production technology and be pressed into soft capsule.
13, containing the preparation of the Eubacterium rectale viable capsule of inulin
First, with liquid or solid culture medium culturing Eubacterium rectale (ATCC article number 33656) strain, then collect and wash thalline, drying is prepared into active microbe powder, then inulin 5 weight portion, Eubacterium rectale active microbe powder 5 weight portion is taken, research of super-pine crush equipment processing is adopted to pulverize, obtain inulin, Eubacterium rectale fine powder that grain diameter is 100 microns, its homogenizing is become mixing fine powders, then content material is placed in soft capsule pellet press, fills according to existing soft capsule production technology and be pressed into soft capsule.
14, the preparation of Eubacterium ramulus viable capsule
Take Eubacterium ramulus (ATCC article number 29099) 10 weight portions, research of super-pine crush equipment processing is adopted to pulverize, obtain the Eubacterium ramulus fine powder that grain diameter is 100 microns, its homogenizing is become mixing fine powders, then content material is placed in soft capsule pellet press, fills according to existing soft capsule production technology and be pressed into soft capsule
15, containing the preparation of the Eubacterium ramulus viable capsule of inulin
First, with liquid or solid culture medium culturing Eubacterium ramulus (ATCC article number 29099) strain, then collect and wash thalline, drying is prepared into active microbe powder, then inulin 5 weight portion, Eubacterium ramulus active microbe powder 5 weight portion is taken, research of super-pine crush equipment processing is adopted to pulverize, obtain inulin, Eubacterium ramulus fine powder that grain diameter is 100 microns, its homogenizing is become mixing fine powders, then content material is placed in soft capsule pellet press, fills according to existing soft capsule production technology and be pressed into soft capsule.
16, the preparation of Eubacterium oxidoreducens capsule
Take Eubacterium oxidoreducens (ATCC article number 43585) 10 weight portions, research of super-pine crush equipment processing is adopted to pulverize, obtain the Eubacterium oxidoreducens fine powder that grain diameter is 100 microns, its homogenizing is become mixing fine powders, then content material is placed in soft capsule pellet press, fills according to existing soft capsule production technology and be pressed into soft capsule
17, containing the preparation of the Eubacterium oxidoreducens viable capsule of inulin
First, with liquid or solid culture medium culturing Eubacterium oxidoreducens (ATCC article number 43585) strain, then collect and wash thalline, drying is prepared into active microbe powder, then inulin 5 weight portion, Eubacterium oxidoreducens active microbe powder 5 weight portion is taken, research of super-pine crush equipment processing is adopted to pulverize, obtain inulin, Eubacterium oxidoreducens fine powder that grain diameter is 100 microns, its homogenizing is become mixing fine powders, then content material is placed in soft capsule pellet press, fills according to existing soft capsule production technology and be pressed into soft capsule.
18, the preparation of Ai Shi Megasphaera capsule
Take Ai Shi Megasphaera (ATCC article number 25940) 10 weight portions, research of super-pine crush equipment processing is adopted to pulverize, obtain the Ai Shi Megasphaera fine powder that grain diameter is 100 microns, its homogenizing is become mixing fine powders, then content material is placed in soft capsule pellet press, fills according to existing soft capsule production technology and be pressed into soft capsule
19, containing the preparation of the Ai Shi Megasphaera viable capsule of inulin
First, with liquid or solid culture medium culturing Ai Shi Megasphaera (ATCC article number 25940) strain, then collect and wash thalline, drying is prepared into active microbe powder, then inulin 5 weight portion, Ai Shi Megasphaera active microbe powder 5 weight portion is taken, research of super-pine crush equipment processing is adopted to pulverize, obtain powder, Ai Shi Megasphaera fine powder that chrysanthemum granules particle diameter is 100 microns, its homogenizing is become mixing fine powders, then content material is placed in soft capsule pellet press, fills according to existing soft capsule production technology and be pressed into soft capsule.
Then, following experiment is carried out with each product of preparation in embodiment 1:
Embodiment 2: regulate human body intestinal canal flora functional experiment
1, the grouping of test-meal experiment
According to the regulating intestinal canal flora function human experiment experimental evaluation way of Ministry of Public Health " health food inspection and assessment technical specification (2003) ", each product of embodiment 1 gained is evaluated, specific as follows:
Here is the grouping of test-meal experiment:
Table 1 test-meal experiment grouped table
2, human experiment experimental technique
Experimenter is divided at random 19 groups, often organizes 10 people, before experimenter's test-meal, all asepticly take experimenter's feces, 16S rDNA checks order inspection intestinal microbial population, as the reference of background level.
By the grouping situation of table 1, group 1 takes clostridium butyricum viable capsule, group 2 takes the clostridium butyricum viable capsule containing inulin, group 3 takes butyric acid bacteria viable capsule, group 4 takes the butyric acid bacteria viable capsule containing inulin, group 5 takes clostridium tertium viable capsule, group 6 takes the clostridium tertium viable capsule containing inulin, group 7 takes Eubacterium ventriosum viable capsule, group 8 takes the Eubacterium ventriosum viable capsule containing inulin, group 9 takes Eubacterium biforme viable capsule, group 10 takes the Eubacterium biforme viable capsule containing inulin, group 11 takes Eubacterium rectale viable capsule, group 12 takes the Eubacterium rectale viable capsule containing inulin, group 13 takes Eubacterium ramulus capsule, group 14 takes the Eubacterium ramulus viable capsule containing inulin, group 15 takes Eubacterium oxidoreducens capsule, group 16 takes the Eubacterium oxidoreducens Eubacterium oxidoreducens capsule containing inulin, group 17 takes Ai Shi Megasphaera viable capsule, group 18 takes the Ai Shi Megasphaera viable capsule containing inulin, group 19 takes inulin capsule, after 4 weeks, takes experimenter's feces, and 16S rDNA checks order and checks intestinal microbial population, contrasts with background level, contrasts the multiple that its relative abundance increases.
3, intestinal microbial population detection method
First fecal sample carries out DNA extraction, V3 ~ V5 region of pcr amplification 16S rDNA, then with 454 platform order-checkings, and order-checking direction V5->V3.Average 7795 tag of each sample initial data, read long about 400bp.The final tag number average out to 3235 for analyzing, reads long about 265bp.
16S analyzes main employing mothur software (http://www.mothur.org/wiki/Mothur_manual), comprises Quality Control, OTU cluster, the analyses such as annotation, and on the basis completing data species taxonomy, analyzes the relative abundance of each species.
4, experimental result
The sequencing data abundance contrast (improving multiple compared with the background level before test-meal) of each Pseudomonas of table 2 people intestinal microbial population
From the experimental result of table 4, test-meal is after 4 weeks, and take experimental group containing the product butyric viable capsule of inulin relative to matched group, the probiotic bacteria quantity such as Eubacterium, bacillus faecalis of dwelling genus, Luo Sibairui Bordetella, Coprecoccus all have obvious increase.Show the quantity of the probiotic bacterias such as edible composition of the present invention can significantly improve Eubacterium in animal intestinal, bacillus faecalis of dwelling genus, Luo Sibairui Bordetella, Coprecoccus, regulating intestinal canal flora Be very effective.
Embodiment 3: blood sugar lowering zoopery
According to the auxiliary hyperglycemic function zoopery evaluation method of Ministry of Public Health " health food inspection and assessment technical specification (2003) ", embodiment 1 products obtained therefrom is evaluated, specific as follows:
1, test method: get male SD rat 190, prepares low dose of streptozotocin according to standard method and causes diabetes rat model, be divided into 19 groups at random after three days according to rat blood sugar value, often organizes 10.Each group of continuous gastric infusion 8 days, every day 1 time, last two hours after administration gets blood, measures blood glucose value.
2, subjects: tested SD rat is divided into 19 groups at random, often organizes 10, tested SD rat primary diet control and movable constant, and by the grouping situation of table 1, group 1 takes clostridium butyricum viable capsule, group 2 takes the clostridium butyricum viable capsule containing inulin, group 3 takes butyric acid bacteria viable capsule, group 4 takes the butyric acid bacteria viable capsule containing inulin, group 5 takes clostridium tertium viable capsule, group 6 takes the clostridium tertium viable capsule containing inulin, group 7 takes Eubacterium ventriosum viable capsule, group 8 takes the Eubacterium ventriosum viable capsule containing inulin, group 9 takes Eubacterium biforme viable capsule, group 10 takes the Eubacterium biforme viable capsule containing inulin, group 11 takes Eubacterium rectale viable capsule, group 12 takes the Eubacterium rectale viable capsule containing inulin, group 13 takes Eubacterium ramulus capsule, group 14 takes the Eubacterium ramulus viable capsule containing inulin, group 15 takes Eubacterium oxidoreducens capsule, group 16 takes the Eubacterium oxidoreducens capsule containing inulin, group 17 takes Ai Shi Megasphaera viable capsule, group 18 takes the Ai Shi Megasphaera viable capsule containing inulin, group 19 takes inulin capsule.
3, experimental result
The hypoglycemic result of different experiments group is as shown in table 3.
Table 3 different experiments group blood sugar decreasing effect compares
Note: (1) compares * P<0.01 with blank group; (2) compare with blank group
△p<0.05
The animal test results of table 3 shows, edible composition group of the present invention all has decline effect to the hyperglycemia of Experimental Diabetes of Mice, particularly containing the clostridium butyricum viable capsule of inulin, containing the butyric acid bacteria viable capsule of inulin, containing the clostridium tertium viable capsule of inulin, the hyperglycemia of Eubacterium rectale viable capsule to Experimental Diabetes of Mice containing inulin has extremely significant decline effect, show edible composition of the present invention and there is hypoglycemic function, and relative to single product butyric or inulin capsule, the action effect of edible composition of the present invention in reduction experiment mice blood glucose is better, inulin in edible composition of the present invention is described, produce butyric and there is chemiluminescence, edible composition of the present invention has obvious technical advantage, to diabetes, there is significant auxiliary therapeutic action.
Embodiment 4: blood fat reducing zoopery
According to the auxiliary lipid-lowering function zoopery evaluation method of Ministry of Public Health " health food inspection and assessment technical specification (2003) ", embodiment 1 products obtained therefrom is evaluated, specific as follows:
1, test material and method:
Wistar male rat 190, body weight 200 ± 20g, is provided by Wuhan University's Experimental Animal Center.Bring out rat hyperlipidemia pathological model formula (high lipid food): in normal feedstuff, add 1% cholesterol, 10% egg yolk, 10% Adeps Sus domestica, dry in bulk.
The preparation method of Hyperlipemia model rat: Wistar male rat is divided at random 19 groups (often organizing 10), i.e. hyperlipemia rat (hyperlipidemia model control group), to feed high lipid food (based on high lipid food formula feedstuff 93.8%, cholesterol 1.0%, Adeps Sus domestica 5.0%, cholate 0.2%), do not give tested material;
Medication: tested Hyperlipemia model rat is divided into 19 groups at random, often organizes 10, the former diet control of tested Hyperlipemia model rat and movable constant, by the grouping situation of table 1, organizes 1 and takes clostridium butyricum viable capsule, group 2 takes the clostridium butyricum viable capsule containing inulin, group 3 takes butyric acid bacteria viable capsule, group 4 takes the butyric acid bacteria viable capsule containing inulin, group 5 takes clostridium tertium viable capsule, group 6 takes the clostridium tertium viable capsule containing inulin, group 7 takes Eubacterium ventriosum viable capsule, group 8 takes the Eubacterium ventriosum viable capsule containing inulin, group 9 takes Eubacterium biforme viable capsule, group 10 takes the Eubacterium biforme viable capsule containing inulin, group 11 takes Eubacterium rectale viable capsule, group 12 takes the Eubacterium rectale viable capsule containing inulin, group 13 takes Eubacterium ramulus capsule, group 14 takes the Eubacterium ramulus viable capsule containing inulin, group 15 takes Eubacterium oxidoreducens capsule, group 16 takes the Eubacterium oxidoreducens capsule containing inulin, group 17 takes Ai Shi Megasphaera viable capsule, group 18 takes the Ai Shi Megasphaera viable capsule containing inulin, group 19 takes inulin capsule.
All animals are all raised 20 days under equivalent environment.After last gives the 4h of each tested material, get hematometry serum total cholesterol (TC mmol/L, iron chloride development process), serum triacylglycerol (TG mmol/L, acetylacetone method), HDL-C (HDL-C mmol/L, phosphotungstic acid method).
2, experimental result
The content of each group of rat blood serum total TG, TC and HDL-C is in table 4.
The effectiveness comparison of TC, TG, HDL-C falls in table 4 different experiments group
Note: (1) * represents P<0.05; (2) * * represents P<0.01
From the above results: compared with before test-meal, take each group of rat containing the product butyric viable capsule of inulin, test-meal is Rat Cholesterol after 30 days, triglyceride comparatively all has obvious reduction before test-meal, high density lipoprotein comparatively has obvious rising before test-meal, and containing the product butyric viable capsule of inulin, single inulin or product butyric capsule are all better than to the effect of adjusting blood lipid, show the inulin in edible composition of the present invention, produce butyric and there is chemiluminescence, edible composition of the present invention has obvious technical advantage, to hyperlipemia, there is significant auxiliary therapeutic action.
Embodiment 5: blood sugar lowering, blood fat reducing human experiment are tested
According to auxiliary hyperglycemic, the hypolipemic function human experiment experimental evaluation way of Ministry of Public Health " health food inspection and assessment technical specification (2003) ", each product of embodiment 1 gained is evaluated, specific as follows:
1, human experiment and test method:
Select 190 routine type Ⅱdiabetes mellitus people, wherein male 140 people by the principle of voluntariness, women 50 people, the range of age 43-75 year, without complication such as severe cardiac Liver and kidney, contrast design after taking in before test-meal.
Experimenter is divided into 19 groups at random, often organizes 10 people, the former medicine kind of experimenter, diet control and movable constant, by the grouping situation of table 1, group 1 takes clostridium butyricum viable capsule, group 2 takes the clostridium butyricum viable capsule containing inulin, group 3 takes butyric acid bacteria viable capsule, group 4 takes the butyric acid bacteria viable capsule containing inulin, group 5 takes clostridium tertium viable capsule, group 6 takes the clostridium tertium viable capsule containing inulin, group 7 takes Eubacterium ventriosum viable capsule, group 8 takes the Eubacterium ventriosum viable capsule containing inulin, group 9 takes Eubacterium biforme viable capsule, group 10 takes the Eubacterium biforme viable capsule containing inulin, group 11 takes Eubacterium rectale viable capsule, group 12 takes the Eubacterium rectale viable capsule containing inulin, group 13 takes Eubacterium ramulus capsule, group 14 takes the Eubacterium ramulus viable capsule containing inulin, group 15 takes Eubacterium oxidoreducens capsule, group 16 takes the Eubacterium oxidoreducens capsule containing inulin, group 17 takes Ai Shi Megasphaera viable capsule, group 18 takes the Ai Shi Megasphaera viable capsule containing inulin, group 19 takes inulin capsule, daily 1 time, in one after each meal, takes 30 days continuously.
The change of monitoring patient blood pressure, defecation, body weight, and the blood glucose (with glucose oxidase method) measuring empty stomach and 2 hours after the meal; Measure blood fat (T-CHOL TC, triglyceride TG and high density lipoprotein HDL-C).
2, judgment criteria:
Effective: fundamental symptoms disappears, on an empty stomach or the blood glucose of 2 hours after the meal comparatively treat before decline and be no more than 30.0%.
Effective: fundamental symptoms obviously improves, on an empty stomach and the blood glucose of 2 hours after the meal comparatively treat before decline and be no more than 10.0%.
Invalid: fundamental symptoms is not improved, on an empty stomach and the blood glucose of 2 hours after the meal comparatively treat before decline and be less than 10.0%.
3, human experiment result:
Test-meal, after 30 days, takes the patient of each product, compared with before test-meal, the blood pressure of patient, defecation, body weight there are no significant difference, but fasting glucose, 2h-plasma glucose all have obvious attenuating, the product butyric viable capsule blood sugar decreasing effect wherein containing inulin is more remarkable, and concrete outcome is in table 5.
Impact about on the blood fat before and after test-meal: the patient taking each product, compared with before test-meal, the cholesterol of test-meal patient after 30 days, triglyceride comparatively all have obvious reduction before test-meal, high density lipoprotein comparatively has obvious rising before test-meal, but more remarkable containing the effect of the product butyric viable capsule blood sugar lowering of inulin, blood fat reducing, concrete outcome is in table 6.
As can be seen here, edible composition of the present invention has the health care of obvious auxiliary hyperglycemic, blood fat reducing, and to the harmless effect of tested population health.
Table 5 foretastes crowd's blood glucose test results
Table 6 foretastes crowd's lipids detection result
Note: (1) * represents P<0.05; (2) * * represents P<0.01
Embodiment 6: Bariatric effect test
According to following steps, each product of Evaluation operation example 1 gained is to the therapeutic effect of obesity:
1, test material and method
Study subject: through health check-up Pass Test requirement, the fat volunteer of overweight degree more than 20% 190, without Other diseases, viscera function is normal.
Method: adopt own control design, experimenter is divided into 19 groups at random, often organizes 10 people, by the grouping situation of table 1, group 1 takes clostridium butyricum viable capsule, group 2 takes the clostridium butyricum viable capsule containing inulin, group 3 takes butyric acid bacteria viable capsule, group 4 takes the butyric acid bacteria viable capsule containing inulin, group 5 takes clostridium tertium viable capsule, group 6 takes the clostridium tertium viable capsule containing inulin, group 7 takes Eubacterium ventriosum viable capsule, group 8 takes the Eubacterium ventriosum viable capsule containing inulin, group 9 takes Eubacterium biforme viable capsule, group 10 takes the Eubacterium biforme viable capsule containing inulin, group 11 takes Eubacterium rectale viable capsule, group 12 takes the Eubacterium rectale viable capsule containing inulin, group 13 takes Eubacterium ramulus capsule, group 14 takes the Eubacterium ramulus viable capsule containing inulin, group 15 takes Eubacterium oxidoreducens capsule, group 16 takes the Eubacterium oxidoreducens capsule containing inulin, group 17 takes Ai Shi Megasphaera viable capsule, group 18 takes the Ai Shi Megasphaera viable capsule containing inulin, group 19 takes inulin capsule, daily 1 time, in one after each meal, takes 30 days continuously.Be consistent before diet and quantity of motion and test during test-meal.Indices in test-meal on-test and at the end of each test 1 time.
2, both effectiveness observation
1. height (cm), body weight (kg) calculate standard body weight, overweight degree is measured:
Adult's standard body weight (kg)=[height (cm)-100] × 0.9,
Overweight degree (%)=(actual measurement body weight-standard body weight)/standard body weight × 100%.
2. body fat total amount (kg) and fat percentage (%) measure: measure Determination of Total Body Fat with electrical impedance instrument.
3. waistline, hip circumference (cm) are measured: use tape measuring.
3, observed result
3.1 body weight, body fat total amount and fat percentage measure
About to the body weight before and after test-meal, body fat, take the patient of each product, compared with before test-meal, the body weight of test-meal patient after 30 days, body fat comparatively all have obvious reduction before test-meal, Rate of body lipid comparatively has obvious rising before test-meal, but more remarkable containing the effect of the product butyric viable capsule of inulin, concrete outcome is in table 7.
Body weight before and after table 7 test-meal, body fat measurement result (
n=190)
Note: (1) * represents P<0.05; (2) * * represents P<0.01
The measurement of 3.2 waistlines, hip circumference
About to the waistline before and after test-meal, hip circumference, take the patient of each product, compared with before test-meal, the waistline of test-meal patient after 30 days, hip circumference comparatively all have obvious reduction before test-meal, but more remarkable containing the effect of the product butyric viable capsule of inulin, concrete outcome is in table 8.
Table 8 test-meal front and back waist, hip circumference measurement result (
n=190)
Note: (1) * represents P<0.05; (2) * * represents P<0.01
From the above results, experimenter takes product butyric viable capsule containing inulin after 30 days continuously, and body weight, body fat total amount, Rate of body lipid, waistline, hip circumference all significantly decline, and effect is better than single inulin or produces butyric capsule.As can be seen here, the inulin in edible composition of the present invention and product butyric have chemiluminescence, have obvious antiobesity action, and have no untoward reaction during taking to human body.
Embodiment 7: hypertension therapeutic effect experimental
According to following steps, each product of Evaluation operation example 1 gained is to hypertensive therapeutic effect:
Wherein, 190 routine hyperpietics, all according to the diagnostic criteria of " new Chinese medicine clinical guidance principle (first volume) ", are diagnosed as hypertension.
1, diagnostic criteria:
Systolic pressure is equal to or higher than 160mmHg(21.3kPa), diastolic pressure is equal to or higher than 95mmHg(12.721.3kPa), both have 1 through examining, and can make a definite diagnosis.
2, Therapeutic Method:
With own control design, experimenter is divided into 19 groups at random, often organizes 10 people, by the grouping situation of table 1, group 1 takes clostridium butyricum viable capsule, group 2 takes the clostridium butyricum viable capsule containing inulin, group 3 takes butyric acid bacteria viable capsule, group 4 takes the butyric acid bacteria viable capsule containing inulin, group 5 takes clostridium tertium viable capsule, group 6 takes the clostridium tertium viable capsule containing inulin, group 7 takes Eubacterium ventriosum viable capsule, group 8 takes the Eubacterium ventriosum viable capsule containing inulin, group 9 takes Eubacterium biforme viable capsule, group 10 takes the Eubacterium biforme viable capsule containing inulin, group 11 takes Eubacterium rectale viable capsule, group 12 takes the Eubacterium rectale viable capsule containing inulin, group 13 takes Eubacterium ramulus capsule, group 14 takes the Eubacterium ramulus viable capsule containing inulin, group 15 takes Eubacterium oxidoreducens capsule, group 16 takes the Eubacterium oxidoreducens capsule containing inulin, group 17 takes Ai Shi Megasphaera viable capsule, group 18 takes the Ai Shi Megasphaera viable capsule containing inulin, group 19 takes inulin capsule, daily 1 time, in one after each meal, takes 30 days continuously.Be consistent before diet and quantity of motion and test during test-meal.Indices in test-meal on-test and at the end of each test 1 time.
According to the criterion of therapeutical effect in " new Chinese medicine clinical guidance principle (first volume) ", effective: 1. diastolic pressure decline 10mmHg(1.3kPa) more than, and reach normal range; Though 2. diastolic pressure is normally not near, with decline 20mmHg(2.7kPa) or more, wherein 1 must be possessed; Effective: 1. diastolic pressure declines not as good as 10mmHg(1.3kPa), but to reach normal range; 2. diastolic pressure comparatively treats the front 10 ~ 19mmHg(1.3 ~ 2.5kPa that declines), but do not reach normal range; 3. systolic pressure comparatively treats front decline 30mmHg(4kPa); Wherein 1 must be possessed; Invalid: not reach above standard.
After each group of case treatment, comparitive study the results are shown in Table 9.
Blood pressure (diastolic pressure) measurement result (mmHg) before and after table 9 test-meal
| Group | Before test-meal (mmHg) | Test-meal is (mmHg) after 30 days |
| Group 1 | 97.3±2.30 | 87.3±2.30* |
| Group 2 | 95.5±1.70 | 85.1±2.60** |
| Group 3 | 101.7±1.40 | 92.3±1.70* |
| Group 4 | 98.5±2.40 | 89.4±2.00* |
| Group 5 | 104.4±2.50 | 90.3±2.30* |
| Group 6 | 105.5±1.50 | 86.7±2.70** |
| Group 7 | 97.7±2.70 | 87.1±1.30* |
| Group 8 | 96.5±1.30 | 85.2±2.30** |
| Group 9 | 98.1±1.30 | 91.3±2.10* |
| Group 10 | 97.5±1.00 | 87.9±2.90* |
| Group 11 | 95.9±2.10 | 90.3±1.50 |
| Group 12 | 97.3±1.20 | 89.3±2.40* |
| Group 13 | 107.7±2.70 | 94.3±1.30** |
| Group 14 | 99.1±1.10 | 89.3±1.70* |
| Group 15 | 96.3±2.60 | 86.3±2.10** |
| Group 16 | 96.5±1.30 | 85.3±1.10** |
| Group 17 | 94.3±2.10 | 87.2±1.30* |
| Group 18 | 95.3±1.90 | 86.6±1.60* |
| Group 19 | 98.4±1.40 | 89.7±1.90* |
Note: (1) * represents effective; (2) * * represents effective
From the above results, in this test-meal test, experimenter takes product butyric viable capsule containing inulin after 30 days continuously, and blood pressure all has decline in various degree, and antihypertensive effect more single product butyric or inulin capsule more obvious.As can be seen here, edible composition of the present invention has obvious hypotensive activity to human body, and has no untoward reaction during taking.
In the description of this description, specific features, structure, material or feature that the description of reference term " embodiment ", " some embodiments ", " example ", " concrete example " or " some examples " etc. means to describe in conjunction with this embodiment or example are contained at least one embodiment of the present invention or example.In this manual, identical embodiment or example are not necessarily referred to the schematic representation of above-mentioned term.And the specific features of description, structure, material or feature can combine in an appropriate manner in any one or more embodiment or example.
Although illustrate and describe embodiments of the invention, those having ordinary skill in the art will appreciate that: can carry out multiple change, amendment, replacement and modification to these embodiments when not departing from principle of the present invention and aim, scope of the present invention is by claim and equivalents thereof.
Claims (10)
1. an edible composition, is characterized in that, comprises:
Weight ratio is the inulin of 1:1 and produces butyric.
2. edible composition according to claim 1, is characterized in that, the grain diameter of described inulin and described product butyric is all not more than 100 microns,
Optionally, described product butyric produces butanoic acid Pseudomonas for being selected from, at least one of fusobacterium, Eubacterium and Fusobacterium,
Optionally, described product butyric be selected from clostridium butyricum, at least one that butyric acid bacteria, clostridium tertium, Eubacterium ventriosum, Eubacterium biforme, Eubacterium rectale, Eubacterium ramulus, Eubacterium oxidoreducens, Ai Shi Megasphaera, polyacid light hilllock Salmonella, Eubacterium hallii, Pu Shi dwell bacillus faecalis
Optionally, the viable count of described product butyric is not less than 1.0*10
8cFU/g,
Optionally, the edible dosage of described edible composition is 200-400mg/kg every day, preferred 300mg/kg.
3. prepare a method for the edible composition described in claim 1 or 2, it is characterized in that,
Be inulin and the product butyric Homogeneous phase mixing of 1:1 by weight ratio.
4. method according to claim 3, is characterized in that, the grain diameter of described inulin and described product butyric is all not more than 100 microns,
Optionally, described product butyric produces butanoic acid Pseudomonas for being selected from, at least one of fusobacterium, Eubacterium and Fusobacterium,
Optionally, described product butyric be selected from clostridium butyricum, at least one that butyric acid bacteria, clostridium tertium, Eubacterium ventriosum, Eubacterium biforme, Eubacterium rectale, Eubacterium ramulus, Eubacterium oxidoreducens, Ai Shi Megasphaera, polyacid light hilllock Salmonella, Eubacterium hallii, Pu Shi dwell bacillus faecalis
Optionally, the viable count of described product butyric is not less than 1.0*10
8cFU/g.
5. the edible composition described in claim 1 or 2 is preparing the purposes in medicine, and described medicine is for regulating microbial population of animal intestinal tract.
6. purposes according to claim 5, is characterized in that, described medicine is used for enhancing immunity, prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor.
7. a medicine, is characterized in that, comprises:
Edible composition described in claim 1 or 2; And
Pharmaceutically acceptable excipient.
8. medicine according to claim 7, is characterized in that, described excipient is at least one being selected from binding agent, filler, film-coating polymer, plasticizer, fluidizer, disintegrating agent and lubricant,
Optionally, described medicine in the form of at least one being selected from capsule, pill, tablet, granule, liquid oral, oral pastes, aerosol and spray,
Optionally, the dosage of described medicine is 100-200mg inulin/kg every day, preferred 150mg inulin/kg,
Optionally, described medicine for regulating microbial population of animal intestinal tract,
Optionally, described medicine is used for enhancing immunity, prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor.
9. a functional food, is characterized in that, comprises:
Edible composition described in claim 1 or 2; And
Acceptable additive in bromatology.
10. functional food according to claim 9, is characterized in that, the edible dosage of described functional food is 100-200mg inulin/kg every day, preferred 150mg inulin/kg,
Optionally, described functional food is used for mediator's intestinal microbial population,
Optionally, described functional food is used for enhancing immunity, prevention or treatment obesity, diabetes, hypertension, hyperlipidemia or tumor.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310391108.3A CN104415060A (en) | 2013-08-30 | 2013-08-30 | Edible composition as well as preparation method and application thereof |
| HK15104084.2A HK1203398A1 (en) | 2013-08-30 | 2015-04-28 | Edible composition, preparation method and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310391108.3A CN104415060A (en) | 2013-08-30 | 2013-08-30 | Edible composition as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104415060A true CN104415060A (en) | 2015-03-18 |
Family
ID=52965884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310391108.3A Pending CN104415060A (en) | 2013-08-30 | 2013-08-30 | Edible composition as well as preparation method and application thereof |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN104415060A (en) |
| HK (1) | HK1203398A1 (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106974939A (en) * | 2016-01-15 | 2017-07-25 | 深圳华大基因研究院 | Application of the heavy wall mushroom probiotics in fat and its relevant disease is treated and prevented |
| CN107028985A (en) * | 2016-02-04 | 2017-08-11 | 深圳华大基因研究院 | Application of the heavy wall mushroom probiotics in preventing and/or treating diabetes and its relevant disease |
| CN107411094A (en) * | 2017-05-12 | 2017-12-01 | 广州赛莱拉干细胞科技股份有限公司 | A kind of composition for improving enteric microorganism and the soft sweets for improving enteric microorganism |
| WO2018027898A1 (en) * | 2016-08-12 | 2018-02-15 | 深圳华大基因研究院 | Faecalibacterium butyricigenerans and method for cultivation thereof and application thereof |
| WO2018045492A1 (en) * | 2016-09-06 | 2018-03-15 | 深圳华大基因研究院 | Faecalibacterium longum and application thereof |
| CN107847530A (en) * | 2015-06-01 | 2018-03-27 | 芝加哥大学 | By controlling symbiotic microorganism clump come treating cancer |
| CN110327375A (en) * | 2019-07-02 | 2019-10-15 | 广东省生物资源应用研究所 | Megasphaera elsdenii reduces the application in total cholesterol and/or low density lipoprotein cholesterol preparation in preparation |
| WO2019215345A1 (en) * | 2018-05-11 | 2019-11-14 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| CN111991427A (en) * | 2019-05-07 | 2020-11-27 | 瑞微（深圳）生物科技有限公司 | Application of intestinal bacteria in preparation of medicine for promoting TCR gamma + T cell proliferation |
| US11007233B2 (en) | 2017-06-14 | 2021-05-18 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
| CN113795572A (en) * | 2018-12-26 | 2021-12-14 | 西班牙高等科研理事会 | HOLDEMANELLA SP. bacterium and use thereof |
| CN114634892A (en) * | 2022-03-24 | 2022-06-17 | 浙江省农业科学院 | Probiotics composition with blood fat reducing function, preparation method and equipment |
| CN113795572B (en) * | 2018-12-26 | 2024-11-19 | 西班牙高等科研理事会 | HOLDEMANELLA SP. bacteria and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080199444A1 (en) * | 2006-06-26 | 2008-08-21 | Yunlong Cui | Composition and method for reducing feces toxins and treating digestive disorders |
| CN101624611A (en) * | 2009-08-13 | 2010-01-13 | 浙江大学 | Preparation method of inulase zymolyte for promoting clostridium butyricum to grow |
-
2013
- 2013-08-30 CN CN201310391108.3A patent/CN104415060A/en active Pending
-
2015
- 2015-04-28 HK HK15104084.2A patent/HK1203398A1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080199444A1 (en) * | 2006-06-26 | 2008-08-21 | Yunlong Cui | Composition and method for reducing feces toxins and treating digestive disorders |
| CN101624611A (en) * | 2009-08-13 | 2010-01-13 | 浙江大学 | Preparation method of inulase zymolyte for promoting clostridium butyricum to grow |
Non-Patent Citations (4)
| Title |
|---|
| SYLVIAH.DUNCAN等: "Effects of Alternative Dietary Substrates on Competition between Human Colonic Bacteria in an Anaerobic Fermentor System", 《AMERICAN SOCIETY FOR MICROBIOLOGY》 * |
| 于卓腾等: "肠道产丁酸细菌及其丁酸产生机制的研究进展", 《世界华人消化杂志》 * |
| 吴英韬等: "微生态制剂在肠内营养治疗的研究进展与应用", 《中国微生态学杂志》 * |
| 王金刚等: "菊粉的工业化生产技术与发展前景", 《食品工业科技》 * |
Cited By (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107847530A (en) * | 2015-06-01 | 2018-03-27 | 芝加哥大学 | By controlling symbiotic microorganism clump come treating cancer |
| CN106974939A (en) * | 2016-01-15 | 2017-07-25 | 深圳华大基因研究院 | Application of the heavy wall mushroom probiotics in fat and its relevant disease is treated and prevented |
| CN107028985A (en) * | 2016-02-04 | 2017-08-11 | 深圳华大基因研究院 | Application of the heavy wall mushroom probiotics in preventing and/or treating diabetes and its relevant disease |
| CN109874329B (en) * | 2016-08-12 | 2023-08-29 | 深圳华大生命科学研究院 | Fusarium butyricum and culture method and application thereof |
| WO2018027898A1 (en) * | 2016-08-12 | 2018-02-15 | 深圳华大基因研究院 | Faecalibacterium butyricigenerans and method for cultivation thereof and application thereof |
| CN109874329A (en) * | 2016-08-12 | 2019-06-11 | 深圳华大生命科学研究院 | A kind of production butyric acid is dwelt bacillus faecalis and its cultural method and application |
| US11191790B2 (en) | 2016-08-12 | 2021-12-07 | Bgi Shenzhen | Biologically pure Faecalibacterium butyricigenerans strain, composition including the same and method for treating ulcerative colitis |
| WO2018045492A1 (en) * | 2016-09-06 | 2018-03-15 | 深圳华大基因研究院 | Faecalibacterium longum and application thereof |
| CN109219656A (en) * | 2016-09-06 | 2019-01-15 | 深圳华大生命科学研究院 | Long dwell bacillus faecalis (Faecalibacterium longum) and its application |
| US10799540B2 (en) | 2016-09-06 | 2020-10-13 | Bgi Shenzhen | Faecalibacterium longum and application thereof |
| CN107411094A (en) * | 2017-05-12 | 2017-12-01 | 广州赛莱拉干细胞科技股份有限公司 | A kind of composition for improving enteric microorganism and the soft sweets for improving enteric microorganism |
| US11779613B2 (en) | 2017-06-14 | 2023-10-10 | Cj Bioscience, Inc. | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
| US11660319B2 (en) | 2017-06-14 | 2023-05-30 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11007233B2 (en) | 2017-06-14 | 2021-05-18 | 4D Pharma Research Limited | Compositions comprising a bacterial strain of the genus Megasphera and uses thereof |
| EP4056192A1 (en) * | 2018-05-11 | 2022-09-14 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| US11419902B2 (en) | 2018-05-11 | 2022-08-23 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| EP4066845A1 (en) * | 2018-05-11 | 2022-10-05 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| WO2019215346A1 (en) * | 2018-05-11 | 2019-11-14 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| WO2019215345A1 (en) * | 2018-05-11 | 2019-11-14 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| CN113795572A (en) * | 2018-12-26 | 2021-12-14 | 西班牙高等科研理事会 | HOLDEMANELLA SP. bacterium and use thereof |
| EP3904500A4 (en) * | 2018-12-26 | 2022-09-28 | Consejo Superior de Investigaciones Científicas (CSIC) | Holdemanella sp. bacterium and use thereof |
| CN113795572B (en) * | 2018-12-26 | 2024-11-19 | 西班牙高等科研理事会 | HOLDEMANELLA SP. bacteria and uses thereof |
| CN111991427A (en) * | 2019-05-07 | 2020-11-27 | 瑞微（深圳）生物科技有限公司 | Application of intestinal bacteria in preparation of medicine for promoting TCR gamma + T cell proliferation |
| CN110327375A (en) * | 2019-07-02 | 2019-10-15 | 广东省生物资源应用研究所 | Megasphaera elsdenii reduces the application in total cholesterol and/or low density lipoprotein cholesterol preparation in preparation |
| CN114634892A (en) * | 2022-03-24 | 2022-06-17 | 浙江省农业科学院 | Probiotics composition with blood fat reducing function, preparation method and equipment |
| CN114634892B (en) * | 2022-03-24 | 2024-07-26 | 浙江省农业科学院 | Probiotic composition with blood lipid reducing effect, preparation method and equipment |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1203398A1 (en) | 2015-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104415060A (en) | Edible composition as well as preparation method and application thereof | |
| CN104413334A (en) | Edible composition as well as preparation method and application thereof | |
| EP2127660B1 (en) | Agent for reducing visceral fat | |
| DK2478910T3 (en) | ANTI-ADIPOSITY AGENT, ANTI-ADIPOSITA NUTRITION OR DRINK, GLUCOSE TOLERANCE EFFECTIVE AGENT, AND NUTRITION OR DRINK FOR IMPROVING GLUCOSE TOLERANCE | |
| CN102791849B (en) | Lactic acid bacterium-containing preparation | |
| CN111254090B (en) | Lactobacillus reuteri with weight losing function and application thereof | |
| CN104740138A (en) | Composition containing aloe, probiotics and prebiotics and application of composition | |
| CN103908585B (en) | For the probiotics fermention compositions of prevention and therapy constipation | |
| CN109789173A (en) | Nano vesicle and application thereof from bacillus bacterium | |
| JP5554994B2 (en) | Lactic acid bacteria-containing preparation | |
| CN113855712B (en) | Composition capable of promoting defecation and application thereof | |
| CN104415061B (en) | Edible composition and its production and use | |
| KR20190118985A (en) | Novel Bifidobacterium longum strain or Lactobacillus rhamnosus strain for preventing or treating obesity and the use thereof | |
| US20170252381A1 (en) | Uses of bacteroides in treatment or prevention of obesity and obesity-related diseases | |
| JP5592640B2 (en) | Antistress agent containing lactic acid bacteria fermented royal jelly, method for producing the same, hypothalamus-pituitary-adrenocortical activity inhibitor, and sympathetic-adrenal medullary activity inhibitor | |
| CN104415027A (en) | Application of allicin in adjusting animal intestinal flora | |
| JP5254682B2 (en) | Skin property improving agent for oral intake | |
| US10350248B2 (en) | Uses of bacteroides in treatment or prevention of obesity and obesity-related diseases | |
| CN111603489A (en) | Microbial inoculum for improving constipation and preparation method thereof | |
| CN108403970B (en) | Prebiotic composition and preparation method and application thereof | |
| KR101809616B1 (en) | A probiotic strain from kefir with anti-obesity effect | |
| CN104415214A (en) | Application of black garlic extract in adjusting animal intestinal flora | |
| CN104739814A (en) | Application of aloe-emodin in regulating animal intestinal flora | |
| CN114404459B (en) | Application of lactobacillus reuteri CCFM1135 in reducing plasma trimethylamine oxide | |
| CN108114004A (en) | Compound probiotic microbial inoculum for carrying out immunization therapy and preparation method thereof can be directly administered |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1203398 Country of ref document: HK |
|
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 518083 11F-3, Beishan industrial complex, 146 Beishan Road, Yantian District, Shenzhen, Guangdong Applicant after: BGI SHENZHEN Co.,Ltd. Applicant after: Shenzhen Huada Sansheng Garden Technology Co.,Ltd. Address before: 518083 11F-3, Beishan industrial complex, 146 Beishan Road, Yantian District, Shenzhen, Guangdong Applicant before: BGI SHENZHEN Co.,Ltd. Applicant before: SHENZHEN BGI AGRICULTURE AND CYCLE ECONOMIC TECHNOLOGY Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180921 Address after: 518083 2 building, Beishan Industrial Zone, 146 Beishan Road, Yantian District, Shenzhen, Guangdong, China, 11 Applicant after: BGI SHENZHEN Co.,Ltd. Applicant after: BGI PRECISION NUTRITION (SHENZHEN) TECHNOLOGY CO.,LTD. Address before: 518083 11F-3, Beishan industrial complex, 146 Beishan Road, Yantian District, Shenzhen, Guangdong Applicant before: BGI SHENZHEN Co.,Ltd. Applicant before: Shenzhen Huada Sansheng Garden Technology Co.,Ltd. |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150318 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1203398 Country of ref document: HK |